SPA
KRYS icon

Sherbrooke Park Advisers’s Krystal Biotech KRYS Stock Holding History

Sherbrooke Park Advisers’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,353
Closed -$369K – 779
2024
Q4 		$369K Sell
2,353
-26
-1% -$4.61K 0.12% 316
2024
Q3 		$433K Buy
2,379
+1,044
+78% +$201K 0.1% 368
2024
Q2 		$245K Sell
1,335
-2,996
-69% -$503K 0.04% 703
2024
Q1 		$771K Buy
+4,331
New +$602K 0.15% 220

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Sherbrooke Park Advisers's KRYS Position: Q1 2025 in Review

Sherbrooke Park Advisers sold out of Krystal Biotech (KRYS) in Q1 2025, closing a stake of 2,353 shares — an estimated $369K sold.

Sherbrooke Park Advisers first reported a position in KRYS in Q1 2024 and held it in 4 quarters. The position peaked at $771K in Q1 2024. 299 funds tracked by Wall St. Rank hold KRYS as of Q1 2025.

  • Sherbrooke Park Advisers reported no remaining Krystal Biotech position as of Q1 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 2,353 Krystal Biotech shares in Q1 2025, an estimated $369K.
  • Sherbrooke Park Advisers first reported a position in Krystal Biotech in Q1 2024 and held it in 4 quarters.
  • Sherbrooke Park Advisers's Krystal Biotech position peaked at $771K in Q1 2024.
  • 299 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q1 2025, filed 15 May 2025.